DOCSLIB.ORG

(R2-CHOP) in Patients with B-Cell Lymphoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(R2-CHOP) in Patients with B-Cell Lymphoma Letters to the Editor 252 Table 1. Results of multivariate analysis for event-free survival, overall REFERENCES survival and relapse-free survival 1 Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 2000; 355: 165–169. Outcome Variable HR 95% CI P-value 2 Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M et al. Clinical characteristics and outcome of children with Down syndrome and acute lympho- EFS BTG1 1.97 0.57–6.84 0.29 blastic leukemia: a Children’s Cancer Group study. Blood 2005; 106: 4043–4049. IKZF1 2.45 1.18–5.07 0.02 3 Buitenkamp T, Forestier E, Heerema NA, van den Heuvel MM, Pieters R, de Haas V ETV6–RUNX1 0.22 0.03–1.74 0.15 et al. Acute Lymphoblastic Leukemia in children with Down Syndrome: a report from WBC X50 Â 109 2.55 0.88–7.39 0.08 the Ponti di Legno Study group. ASH: San Diego, 2011. Age X10 years 1.29 0.59–2.85 0.52 4 Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with OS BTG1 2.24 0.63–7.91 0.21 Down syndrome: an iBFM-SG study. Blood 2008; 111: 1575–1583. IKZF1 2.02 0.95–4.29 0.06 5 Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J et al. ETV6–RUNX1 0.21 0.03–1.67 0.14 Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease WBC X50 Â 109 2.49 0.85–7.26 0.09 in which aberrant expression of CRLF2 is associated with mutated JAK2: a report AgeX 10 years 1.20 0.52–2.76 0.66 from the International BFM Study Group. Blood 2010; 115: 1006–1017. 6 Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J et al. Abbreviations: CI, confidence interval; EFS, event-free survival; HR, hazard Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute ratio; OS, overall survival. lymphoblastic leukemia. Nat Genet 2009; 41: 1243–1246. 7 Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758–764. ACKNOWLEDGEMENTS 8 Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JP, Beverloo HB et al. Outcome in children with Down syndrome and acute lymphoblastic This study was supported by research funding from the foundation Kinderen leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012; e-pub Kankervrij (KIKA) to TDB and CMZ and the Leukemia and Lymphoma Research (LLR) ahead of print 22 March 2012; doi:10.1038/leu.2012.84. to CS, CJH and AVM. 9 Kuiper RP, Schoenmakers EF, van Reijmersdal SV, Hehir-Kwa JY, van Kessel AG, van Leeuwen FN et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte dif- ferentiation and cell cycle progression. Leukemia 2007; 21: 1258–1266. TD Buitenkamp1, R Pieters1,2, M Zimmermann3, V de Haas2, 10 Tsuzuki S, Karnan S, Horibe K, Matsumoto K, Kato K, Inukai T et al. Genetic SM Richards4, AJ Vora5, CD Mitchell6, C Schwab7, CJ Harrison7, abnormalities involved in t(12;21) TEL-AML1 acute lymphoblastic leukemia: AV Moorman7, MM van den Heuvel-Eibrink1 and CM Zwaan1 analysis by means of array-based comparative genomic hybridization. Cancer Sci 1Pediatric Oncology/Hematology, Erasmus MC–Sophia 2007; 98: 698–706. 11 Rouault JP, Rimokh R, Tessa C, Paranhos G, Ffrench M, Duret L et al. BTG1, a Children’s Hospital, Rotterdam, The Netherlands; 2 member of a new family of antiproliferative genes. Embo J 1992; 11: 1663–1670. Dutch Childhood Oncology Group, Den Haag, The Netherlands; 12 Rimokh R, Rouault JP, Wahbi K, Gadoux M, Lafage M, Archimbaud E et al. A 3 Acute Myeloid Leukemia-Berlin-Frankfurt-Mu¨nster Study Group, chromosome 12 coding region is juxtaposed to the MYC protooncogene locus in Pediatric -Hematology/Oncology, Medical School Hannover, a t(8;12)(q24;q22) translocation in a case of B-cell chronic lymphocytic leukemia. Hannover, Germany; Genes Chromosomes Cancer 1991; 3: 24–36. 4Clinical Trial Service Unit, University of Oxford, Oxford, UK; 13 Rouault JP, Samarut C, Duret L, Tessa C, Samarut J, Magaud JP. Sequence analysis 5Department of Haematology, Sheffield Children’s Hospital, reveals that the BTG1 anti-proliferative gene is conserved throughout evolution in Sheffield, UK; its coding and 3’ non-coding regions. Gene 1993; 129: 303–306. 6Department of Paediatric Haematology/Oncology, 14 Lundin C, Hjorth L, Behrendtz M, Nordgren A, Palmqvist L, Andersen MK et al. High frequency of BTG1 deletions in acute lymphoblastic leukemia in children John Radcliffe Hospital, Oxford, UK and 7 with down syndrome. Genes Chromosomes Cancer 2012; 51: 196–206. Leukaemia Research Cytogenetics Group, Northern Institute for 15 van Galen JC, Kuiper RP, van Emst L, Levers M, Tijchon E, Scheijen B et al. BTG1 Cancer Research, Newcastle University, Newcastle, UK regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. E-mail: [email protected] Blood 2010; 115: 4810–4819. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma Leukemia (2013) 27, 252–255; doi:10.1038/leu.2012.172 association with standard 21-day R-CHOP (R2-CHOP). Dose of lenalidomide was assessed during the first two cycles. Secondary objectives were to assess the safety and efficacy of R2-CHOP for a We were very interested by the article by Nowakowski et al.1 maximum of six cycles. describing the combination of lenalidomide and R-CHOP Patients from 18 to 70 years of age had documented B-cell in patients with aggressive lymphoma. Our group conducted CD20-positive lymphoma: mantle cell lymphoma, marginal zone a similar phase 1b study of this combination in a lymphoma, lymphocytic lymphoma, follicular lymphoma, diffuse patient population with predominantly indolent B-cell large B-cell lymphoma or histological transformation from low lymphoma. grade to high grade lymphoma. Lenalidomide (5, 10, 15, 20 or The primary objective of the study was to determine the 25 mg once daily) was escalated in serial patient cohorts using a recommended dose of lenalinomide administered for 14 days in standard 3 þ 3 design. Each cycle of R2-CHOP comprised the Accepted article preview online 26 June 2012; advance online publication, 13 July 2012 Leukemia (2013) 233 – 258 & 2013 Macmillan Publishers Limited Letters to the Editor 253 dose of lenalidomide from day 1 to day 14 in combination with episodes occurred despite aspirin prophylaxis. One patient, the 375 mg/m2 of rituximab, 50 mg/m2 of doxorubicin, 750 mg/m2 of one who was 77 years old, had a pulmonary embolism and cyclophosphamide and 1.4 mg/m2 of vincristine (up to a maximal recovered rapidly with anticoagulation therapy and one patient dose of 2 mg, in 50–100 ml normal saline in 10–20 min i.v. infusion had a deep venous thrombosis related to the central catheter. after cyclophosphamide) on day 1 and 60 mg/m2 of prednisone Seven patients had a mild rash attributed to lenalidomide. We did on days 1 through 5. Pegfilgrastim was given at day 4 of each not observe grade 3–4 neuropathy but nine patients experienced cycle at a dose of 6 mg.2 Aspirin prophylaxis (100 mg daily) was grade 1 and four patients had grade 2 sensory neuropathy. mandatory during the study period. A prophylaxis of Two patients had vincristine discontinuation at cycle 4 and 6, Pneumocystic jirovecii pneumonia was recommended during respectively. the study and until 3 months after last cycle administration. Dose escalation was determined by the number of dose limiting toxicities (DLTs) observed during the administration of the two RESPONSE TO TREATMENT first cycles of R2-CHOP. DLTs were defined as any grade 3–4 non- Response according to lenalidomide dose is given in hematological toxicity, grade 3 neutropenia or thombocytopenia Supplemental Table 1. The overall response rate was 96%, with lasting more than 7 days, or grade 4 neutropenia or thombocy- 74% of patients achieving a complete remission (CR/CRu). topenia lasting more than 3 days. Once maximal tolerated dose Only one patient with disseminated follicular lymphoma had was reached, the cohort was expanded to a total of 12 patients. histological transformation with meningeal involvement after the There was no individual dose adjustment of lenalidomide. If a fifth cycle. patient experienced a DLT, lenalidomide treatment was defini- tively stopped and the patient continued on treatment with R-CHOP. There was no dose adjustment of R-CHOP in case DISCUSSION of hematological toxicity or failure to recover neutrophil count of Results of this 1b trial of the combination of R-CHOP and 1.5 Â 109/l or platelet count o100 Â 109/l at day 21, but the next lenalidomide confirm the results from Nowakowski et al.1 The cycle could be postponed for a maximum of 7 additional days toxicity profile was similar in the two studies resulting in (day 28). If grade 1 neurological toxicity was related to vincristine, infrequent discontinuation of lenalidomide and only few delays the dose was reduced to 1 mg. If the neurological toxicity related to slow hematological recovery. Although primary increased despite of dose reduction, vincristine was stopped. prophylaxis with pegfiltrastim was used in both studies, the All patients provided written informed consent. The study was potentially lower incidence of grade 4 neutropenia in our study approved by the Comite´ de Protection des Personnes Sud-Est II, could be due to the administration of this drug on day 4 of the Lyon, France and by the regulatory authorities.
Load more

Recommended publications
  • HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 2)
    HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 2) The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, and comorbidities. Thus, the optimal delivery of anticancer agents requires a healthcare delivery team experienced in the use of such agents and the management of associated toxicities in patients with cancer. The cancer treatment regimens below may include both FDA-approved and unapproved uses/regimens and are provided as references only to the latest treatment strategies. Clinicians must choose and verify treatment options based on the individual patient. NOTE: GREY SHADED BOXES CONTAIN UPDATED REGIMENS. REGIMEN DOSING Classical Hodgkin Lymphoma—First-Line Treatment General treatment note: Routine use of growth factors is not recommended. Leukopenia is not a factor for treatment delay or dose reduction (except for escalated BEACOPP).1 CR=complete response IPS=International Prognostic Score PD=progressive disease PFTs=pulmonary function tests PR=partial response RT=radiation therapy SD=stable disease Stage IA, IIA Favorable ABVD (doxorubicin [Adriamycin] Days 1 and 15: Doxorubicin 25mg/m2 IV + bleomycin 10mg/m2 IV + vinblastine + bleomycin + vinblastine + 6mg/m2 IV + dacarbazine 375mg/m2 IV. dacarbazine [DTIC-Dome]) + Repeat cycle every 4 weeks for 2–4 cycles. involved-field radiotherapy (IFRT)1–4 Follow with IFRT after completion of chemotherapy. Abbreviated Stanford V Weeks 1, 3, 5 and 7: Vinblastine 6mg/m2 IV + doxorubicin 25mg/m2 IV. (doxorubicin + vinblastine + Weeks 1 and 5: Mechlorethamine 6mg/m2.
    [Show full text]
  • Lymphoproliferative Disorders
    Lymphoproliferative disorders Dr. Mansour Aljabry Definition Lymphoproliferative disorders Several clinical conditions in which lymphocytes are produced in excessive quantities ( Lymphocytosis) Lymphoma Malignant lymphoid mass involving the lymphoid tissues (± other tissues e.g : skin ,GIT ,CNS …) Lymphoid leukemia Malignant proliferation of lymphoid cells in Bone marrow and peripheral blood (± other tissues e.g : lymph nods ,spleen , skin ,GIT ,CNS …) Lymphoproliferative disorders Autoimmune Infection Malignant Lymphocytosis 1- Viral infection : •Infectious mononucleosis ,cytomegalovirus ,rubella, hepatitis, adenoviruses, varicella…. 2- Some bacterial infection: (Pertussis ,brucellosis …) 3-Immune : SLE , Allergic drug reactions 4- Other conditions:, splenectomy, dermatitis ,hyperthyroidism metastatic carcinoma….) 5- Chronic lymphocytic leukemia (CLL) 6-Other lymphomas: Mantle cell lymphoma ,Hodgkin lymphoma… Infectious mononucleosis An acute, infectious disease, caused by Epstein-Barr virus and characterized by • fever • swollen lymph nodes (painful) • Sore throat, • atypical lymphocyte • Affect young people ( usually) Malignant Lymphoproliferative Disorders ALL CLL Lymphomas MM naïve B-lymphocytes Plasma Lymphoid cells progenitor T-lymphocytes AML Myeloproliferative disorders Hematopoietic Myeloid Neutrophils stem cell progenitor Eosinophils Basophils Monocytes Platelets Red cells Malignant Lymphoproliferative disorders Immature Mature ALL Lymphoma Lymphoid leukemia CLL Hairy cell leukemia Non Hodgkin lymphoma Hodgkin lymphoma T- prolymphocytic
    [Show full text]
  • (Rituxan®), Rituximab-Abbs (Truxima®), Rituximab-Pvvr (Ruxience®) Prior Authorization Drug Coverage Policy
    1 Rituximab Products: Rituximab (Rituxan®), Rituximab-abbs (Truxima®), Rituximab-pvvr (Ruxience®) Prior Authorization Drug Coverage Policy Effective Date: 2/1/2021 Revision Date: n/a Review Date: 7/2/20 Lines of Business: Commercial Policy type: Prior Authorization This Drug Coverage Policy provides parameters for the coverage of rituximab (Rituxan®), rituximab-abbs (Truxima®), and rituximab-pvvr (Ruxience®). Consideration of medically necessary indications are based upon U.S. Food and Drug Administration (FDA) indications, recommended uses within the Centers of Medicare & Medicaid Services (CMS) five recognized compendia, including the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium (Category 1 or 2A recommendations), and peer-reviewed scientific literature eligible for coverage according to the CMS, Medicare Benefit Policy Manual, Chapter 15, section 50.4.5 titled, “Off- Label Use of Anti-Cancer Drugs and Biologics.” This policy evaluates whether the drug therapy is proven to be effective based on published evidence-based medicine. Drug Description1-3 Rituximab (Rituxan®), rituximab-abbs (Truxima®), and rituximab-pvvr (Ruxience®) are monoclonal antibodies that target the CD20 antigen expressed on the surface of pre-B and mature B- lymphocytes. Upon binding to cluster of differentiation (CD) 20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC). B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production.
    [Show full text]
  • R-Chop-21 / Chop-21
    Lymphoma group R-CHOP-21 / CHOP-21 INDICATION Lymphoma Omit rituximab if CD20-negative. TREATMENT INTENT Curative or disease modification depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy and document in notes. 2. Record stage and IPI of disease - CT scan (neck, chest, abdomen and pelvis), and/or PET- CT, presence or absence of B symptoms, clinical extent of disease, consider bone marrow aspirate and trephine. 3. Blood tests – FBC, U&Es, LDH, ESR, urate, calcium, Vitamin D level,magnesium, creatinine, LFTs, glucose, Igs, β2 microglobulin, hepatitis B core antibody and hepatitis B surface Ag, hepatitis C antibody, EBV, CMV, VZV, HIV 1+2 after consent, group and save. 4. Urine pregnancy test • before cycle 1 of each new chemotherapy course for women of child- bearing age unless they are post-menopausal, have been sterilised or undergone a hysterectomy. 5. ECG +/- Echo and baseline BP in all patients with a cardiac history or at risk of cardiac complications (hypertension, smokers, diabetes). 6. Record performance status (WHO/ECOG). 7. Record height and weight. 8. Consent - ensure patient has received adequate verbal and written information regarding their disease, treatment and potential side effects. Document in medical notes all information that has been given. Obtain written consent on the day of treatment. 9. Fertility - it is very important the patient understands the potential risk of infertility. All patients should be offered fertility advice by referring to the Oxford Fertility Unit. 10. Hydration – in patients with bulky disease pre-hydrate with sodium chloride 0.9% 1 litre over 4- 6 hours.
    [Show full text]
  • Anaplastic Large Cell Lymphoma (ALCL)
    Helpline (freephone) 0808 808 5555 [email protected] www.lymphoma-action.org.uk Anaplastic large cell lymphoma (ALCL) This page is about anaplastic large-cell lymphoma (ALCL), a type of T-cell lymphoma. On this page What is ALCL? Who gets it? Symptoms Treatment Relapsed and refractory ALCL Research and targeted treatments We have separate information about the topics in bold font. Please get in touch if you’d like to request copies or if you would like further information about any aspect of lymphoma. Phone 0808 808 5555 or email [email protected]. What is ALCL? Anaplastic large cell lymphoma (ALCL) is a type of T-cell lymphoma – a non-Hodgkin lymphoma that develops from white blood cells called T cells. Under a microscope, the cancerous cells in ALCL look large, undeveloped and very abnormal (‘anaplastic’). There are four main types of ALCL. They have complicated names based on their features and the types of proteins they make: • ALK-positive ALCL (also known as ALK+ ALCL) is the most common type. In ALK-positive ALCL, the abnormal T cells have a genetic change (mutation) that means they make a protein called ‘anaplastic lymphoma kinase’ (ALK). In other words, they test positive for ALK. ALK-positive ALCL is a fast-growing (high-grade) lymphoma. Page 1 of 6 © Lymphoma Action • ALK-negative ALCL (also known as ALK- ALCL) is a high-grade lymphoma that accounts for around 3 in every 10 cases of ALCL. The abnormal T cells do not make the ALK protein – they test negative for ALK.
    [Show full text]
  • Arrhythmia Burden in Patients with Indolent Lymphoma
    Arrhythmia Burden in Patients with Indolent Lymphoma Mujtaba Soniwala DO1, Saadia Sherazi MD1, MS, Susan Schleede MS1, Scott McNitt MS1, Tina Faugh2, Jeremiah Moore PharmD2, Justin Foster PharmD1, Clive Zent MD2, Paul Barr MD2, Patrick Reagan MD2, Jonathan W Friedberg MD2, MSSc, Eugene Storozynsky MD PhD1, Ilan Goldenberg MD1, Carla Casulo MD2 1Department of Medicine, University of Rochester School of Medicine and Dentistry; 2Wilmot Cancer Institute, University of Rochester Medical Center Introduction Results Conclusions Indolent Non-Hodgkin lymphomas (NHL) comprise a • This real-world cohort demonstrates that patients with heterogeneous group of diseases including marginal zone indolent lymphoma could have an increased risk of cardiac lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), arrhythmias that is possibly exacerbated by treatment. small lymphocytic lymphoma/chronic lymphocytic • Atrial fibrillation was the most common arrhythmia leukemia (SLL/CLL), and follicular lymphoma (FL). These identified in this study and appears increased compared to compose a heterogenous group of disorders that frequently the incidence in the general age matched population (1-1.8 measures survival in years due to the long natural history of per 100 person-years). these diseases. Frequency and morbidity of cardiac • Surprisingly, of 80 deaths, 8 (10%) were attributed to arrhythmias in patients with indolent lymphoma is Arrhythmia Incidence Subtype of Indolent Lymphoma sudden cardiac death. unknown, but recent observations note that arrhythmias are • This data set contributes important information that can help an increasing problem. Due to advances in treatment for Arrhythmia incidence by CLL = 89 (53%) FL = 35 (21%) MZL = 27 (16%) LPL = 17 (10%) lymphoma subtype of total identify patients at increased risk of cardiovascular indolent NHL with emergence of novel therapeutics, (N = 168) Arrhythmia incidence Combination Targeted Therapy = Monoclonal Chemotherapy morbidity and mortality that can impact treatment.
    [Show full text]
  • Mantle Cell Lymphoma (MCL)
    Mantle Cell Lymphoma (MCL) Page 1 of 9 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. PATHOLOGIC DIAGNOSIS INITIAL EVALUATION ESSENTIAL: ● Physical exam: attention to node-bearing areas, including Waldeyer's ring, ESSENTIAL: size of liver and spleen, and patient’s age ● Hematopathology review of all slides with at least one tumor paraffin block. ● Performance status (ECOG) Hematopathology confirmation of classic versus aggressive variant of MCL ● B symptoms (fever, drenching night sweats, unintentional weight loss) (blastoid/pleomorphic). Re-biopsy if consult material is non-diagnostic. ● CBC with differential, LDH, BUN, creatinine, albumin, AST, total bilirubin, 1 ● Adequate immunophenotype to confirm diagnosis alkaline phosphatase, serum calcium, uric acid ○ Paraffin panel: ● Screening for HIV 1 and 2, hepatitis B and C (HBcAb, HBaAg, HCVAb) - Pan B-cell marker (CD19, CD20, PAX5), CD3, CD5, CD10, and cyclin D1 ● Beta-2 microglobulin (B2M) - Ki-67 (proliferation rate) ● Chest x-ray, PA and lateral or ● Bone marrow bilateral biopsy with unilateral aspirate Induction ○ Flow cytometry immunophenotyping:
    [Show full text]
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’S Lymphomas Version 2.2015
    NCCN Guidelines Index NHL Table of Contents Discussion NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’s Lymphomas Version 2.2015 NCCN.org Continue Version 2.2015, 03/03/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® . Peripheral T-Cell Lymphomas NCCN Guidelines Version 2.2015 NCCN Guidelines Index NHL Table of Contents Peripheral T-Cell Lymphomas Discussion DIAGNOSIS SUBTYPES ESSENTIAL: · Review of all slides with at least one paraffin block representative of the tumor should be done by a hematopathologist with expertise in the diagnosis of PTCL. Rebiopsy if consult material is nondiagnostic. · An FNA alone is not sufficient for the initial diagnosis of peripheral T-cell lymphoma. Subtypes included: · Adequate immunophenotyping to establish diagnosisa,b · Peripheral T-cell lymphoma (PTCL), NOS > IHC panel: CD20, CD3, CD10, BCL6, Ki-67, CD5, CD30, CD2, · Angioimmunoblastic T-cell lymphoma (AITL)d See Workup CD4, CD8, CD7, CD56, CD57 CD21, CD23, EBER-ISH, ALK · Anaplastic large cell lymphoma (ALCL), ALK positive (TCEL-2) or · ALCL, ALK negative > Cell surface marker analysis by flow cytometry: · Enteropathy-associated T-cell lymphoma (EATL) kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20, CD30, CD4, CD8, CD7, CD2; TCRαβ; TCRγ Subtypesnot included: · Primary cutaneous ALCL USEFUL UNDER CERTAIN CIRCUMSTANCES: · All other T-cell lymphomas · Molecular analysis to detect: antigen receptor gene rearrangements; t(2;5) and variants · Additional immunohistochemical studies to establish Extranodal NK/T-cell lymphoma, nasal type (See NKTL-1) lymphoma subtype:βγ F1, TCR-C M1, CD279/PD1, CXCL-13 · Cytogenetics to establish clonality · Assessment of HTLV-1c serology in at-risk populations.
    [Show full text]
  • Analysis Compared with Classical Hodgkin Lymphoma
    From bloodjournal.hematologylibrary.org by guest on July 21, 2014. For personal use only. 2014 123: 3567-3573 doi:10.1182/blood-2013-12-541078 originally published online April 8, 2014 Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis Katharine H. Xing, Joseph M. Connors, Anky Lai, Mubarak Al-Mansour, Laurie H. Sehn, Diego Villa, Richard Klasa, Tamara Shenkier, Randy D. Gascoyne, Brian Skinnider and Kerry J. Savage Updated information and services can be found at: http://bloodjournal.hematologylibrary.org/content/123/23/3567.full.html Articles on similar topics can be found in the following Blood collections Clinical Trials and Observations (3892 articles) Free Research Articles (2531 articles) Lymphoid Neoplasia (1767 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved. From bloodjournal.hematologylibrary.org by guest on July 21, 2014. For personal use only. Regular Article CLINICAL TRIALS AND OBSERVATIONS Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis Katharine H.
    [Show full text]
  • Non-Hodgkin Lymphoma
    Non-Hodgkin Lymphoma Rick, non-Hodgkin lymphoma survivor This publication was supported in part by grants from Revised 2013 A Message From John Walter President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) believes we are living at an extraordinary moment. LLS is committed to bringing you the most up-to-date blood cancer information. We know how important it is for you to have an accurate understanding of your diagnosis, treatment and support options. An important part of our mission is bringing you the latest information about advances in treatment for non-Hodgkin lymphoma, so you can work with your healthcare team to determine the best options for the best outcomes. Our vision is that one day the great majority of people who have been diagnosed with non-Hodgkin lymphoma will be cured or will be able to manage their disease with a good quality of life. We hope that the information in this publication will help you along your journey. LLS is the world’s largest voluntary health organization dedicated to funding blood cancer research, education and patient services. Since 1954, LLS has been a driving force behind almost every treatment breakthrough for patients with blood cancers, and we have awarded almost $1 billion to fund blood cancer research. Our commitment to pioneering science has contributed to an unprecedented rise in survival rates for people with many different blood cancers. Until there is a cure, LLS will continue to invest in research, patient support programs and services that improve the quality of life for patients and families.
    [Show full text]
  • Bendamustine Plus Rituximab: Is It a BRIGHT Idea?
    Editorial Commentary Page 1 of 4 Bendamustine plus rituximab: is it a BRIGHT idea? Carlo Visco1, Francesca Maria Quaglia1, Chiara Bovo2, Maria Chiara Tisi3, Mauro Krampera1 1Department of Medicine, Section of Hematology, University of Verona, Verona, Italy; 2Medical Direction, University Hospital of Verona, Verona, Italy; 3Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy Correspondence to: Carlo Visco, MD. Associate Professor of Hematology, Department of Medicine, Section of Hematology, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy. Email: [email protected]. Provenance and Peer Review: This article was commissioned and reviewed by the Section Editor Xinyi Du (Department of Hematology, Northern Jiangsu People’s Hospital, Yangzhou, China). Comment on: Flinn IW, van der Jagt R, Kahl B, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol 2019;37:984-91. Submitted Sep 20, 2019. Accepted for publication Oct 14, 2019. doi: 10.21037/cco.2019.10.03 View this article at: http://dx.doi.org/10.21037/cco.2019.10.03 Flinn et al. have reported the results of the long-term in the BRIGHT study were eagerly awaited. As the Stil- follow-up for the BRIGHT trial, an international study 1 trial, the BRIGHT study (3) included patients with which compared the efficacy and the safety of bendamustine follicular lymphoma (grade 1 or 2, excluding grade 3A), plus rituximab (BR) with either rituximab plus lymphoplasmacytic lymphoma, splenic marginal zone B-cell cyclophosphamide, doxorubicin, vincristine, and prednisone lymphoma, extranodal marginal zone lymphoma (MZL) (R-CHOP) or rituximab plus cyclophosphamide, vincristine, of mucosa-associated lymphoid tissue type, nodal marginal and prednisone (R-CVP) for treatment-naive patients with zone B-cell lymphoma (371 patients with iNHL), or MCL indolent non-Hodgkin lymphoma (iNHL) or mantle-cell (74 patients).
    [Show full text]
  • Indolent Lymphoma in Dogs
    Indolent Lymphoma in Dogs You diagnose indolent lymphoma in a dog. What is indolent lymphoma? What is the prognosis and what are the treatment options? What is indolent lymphoma? Indolent lymphoma (also called small-cell or low-grade lymphoma) is an uncommon form of lymphoma in dogs, representing around 5-29%1 of all canine lymphoma. The subtypes described include follicular lymphoma, marginal zone lymphoma, mantle zone and T-zone lymphoma, which are all derived from B-cells (except for T-zone lymphoma, which is T-cell in origin).2,3 In general, indolent lymphoma is characterised by small lymphocytes, a low mitotic index and slow clinical course of progression. Most dogs with indolent lymphoma present with generalised lymphadenopathy. Some dogs present with solitary lymph node involvement or only splenic involvement. Few dogs present with clinical signs, and if clinical signs are present (including lymphadenopathy), it can wax and wane and is usually mild. T-zone lymphoma (TZL) T-zone lymphoma is the most common subtype in canine indolent lymphoma representing around 60% of dogs with indolent lymphoma.1 TZL is characterised by unique loss of CD45 expression, T-zone distinct histologic pattern and small clear cell cytomorphology.4-6 This subtype is associated with the longest median survival times in dogs with indolent lymphoma.1 Middle-aged to older dogs are primarily affected (median age 8 to 10 years).5 Common breeds affected include Golden retriever (40-50%)6,7 and Shih Tzu.5 There is no apparent gender predilection. Dogs typically present with generalised peripheral lymphadenopathy (that may wax and wane) and/or lymphocytosis with no clinical signs of illness (clinical substage a, 80%).5 If clinical signs are present, it is usually non-specific and mild.
    [Show full text]